-
EP1980626
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1980626
| EP1980626 - Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 25.09.2009 Database last updated on 16.11.2024 | Most recent event Tooltip | 25.09.2009 | Application deemed to be withdrawn | published on 28.10.2009 [2009/44] | Applicant(s) | For all designated states Het Nederlands Kanker Instituut Plesmanlaan 121 1066 CX Amsterdam / NL | [2008/42] | Inventor(s) | 01 /
Berns, Katrien Schaepmanlaan 1 2061 LX Bloemendaal / NL | 02 /
Bernards, René Koningsvaren 37 1391 AD Abcoude / NL | [2008/42] | Representative(s) | van Loon, C.J.J., et al Vereenigde Johan de Wittlaan 7 2517 JR Den Haag / NL | [N/P] |
| Former [2008/42] | van Loon, C.J.J., et al Vereenigde Johan de Wittlaan 7 2517 JR Den Haag / NL | Application number, filing date | 07106144.4 | 13.04.2007 | [2008/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP1980626 | Date: | 15.10.2008 | Language: | EN | [2008/42] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 10.10.2007 | Classification | IPC: | C12Q1/68 | [2008/42] | CPC: |
C12Q1/6886 (EP,US);
C12Q2600/106 (EP,US);
C12Q2600/16 (EP,US);
C12Q2600/178 (EP,US)
| Designated contracting states | (deleted) [2009/26] |
| Former [2008/42] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | Lipidkinasebeteiligung und Signaltransduktionsweg mit besagter Lipidkinase als Resistenz gegen HER2-Targeting-Therapie | [2008/42] | English: | Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy | [2008/42] | French: | Implication de kinase de lipide, et passage de transduction du signal comportant cette kinase de lipide, en résistance à la thérapie de ciblage HER2 | [2008/42] | Examination procedure | 16.04.2009 | Application deemed to be withdrawn, date of legal effect [2009/44] | 15.06.2009 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2009/44] | Fees paid | Penalty fee | Additional fee for renewal fee | 30.04.2009 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] - FUJITA T ET AL, "PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer", BRITISH JOURNAL OF CANCER, (200601), vol. 94, no. 2, ISSN 0007-0920, pages 247 - 252, XP002449978 [X] 1-7,9-11 * the whole document * DOI: http://dx.doi.org/10.1038/sj.bjc.6602926 | [X] - NAGATA YOICHI ET AL, "PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients", CANCER CELL, (200408), vol. 6, no. 2, ISSN 1535-6108, pages 117 - 127, XP002449979 [X] 1-7,9-11 * the whole document * DOI: http://dx.doi.org/10.1016/j.ccr.2004.06.022 | [A] - MANO M S ET AL, "Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and P13K-Akt pathways activation", BREAST, (200408), vol. 13, no. 4, ISSN 0960-9776, pages 347 - 349, XP002449980 [A] * the whole document * | [A] - DIERAS VERONIQUE ET AL, "Trastuzumab (Herceptin (R)) and breast cancer: mechanisms of resistance", BULLETIN DU CANCER (MONTROUGE), (200703), vol. 94, no. 3, ISSN 0007-4551, pages 259 - 266, XP008083431 [A] * the whole document * |